Memantine Merz

Memantine Hydrochloride, the active ingredient in Memantine Merz, is an NMDA receptor antagonist presented as an oral tablet for oral use. It is indicated for the treatment of moderate to severe Alzheimer’s disease in adult patients.

GNH USA supplies Memantine Merz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU GMP standards and provides reliable logistics for regulated markets. Customers benefit from consistent product quality, comprehensive documentation, and responsive technical support throughout the supply chain.

Memantine Merz is used in the Alzheimer’s disease therapeutic pathway to address cognitive decline. - Moderate Alzheimer’s disease: may improve cognition and daily functioning in patients with moderate disease severity. - Severe Alzheimer’s disease: may help maintain functional abilities and reduce behavioral symptoms in advanced stages. - Overall Alzheimer’s disease management: used as part of a comprehensive treatment plan to support memory and executive function.

Memantine Merz may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness - Headache - Constipation - Fatigue

Serious or Rare Side Effects: - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Seizures - Severe allergic reactions (anaphylaxis)

When prescribing Memantine Merz, clinicians should consider several precautionary measures to ensure safe use. - Renal impairment: assess kidney function and adjust dose if necessary. - Hepatic impairment: use with caution and monitor liver enzymes. - History of seizures: monitor for increased seizure activity. - Concomitant NMDA antagonists: avoid combined use to reduce risk of neurotoxicity. - Pregnancy and lactation: risk unknown; avoid unless benefit outweighs potential harm. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture and light.

Memantine Merz can interact with other medicines, influencing its plasma levels or therapeutic effect.

Major Interactions (Avoid): - Other NMDA antagonists (e.g., amantadine, dextromethorphan): may increase neurotoxicity. - Strong renal excretion inhibitors (e.g., cimetidine, trimethoprim): can raise memantine concentrations. - High-dose anticholinergic agents: may diminish cognitive benefits.

Moderate Interactions (Monitor Closely): - CNS depressants (e.g., benzodiazepines, opioids): may enhance sedation. - Diuretics (e.g., furosemide): may affect renal clearance of memantine. - Anticholinergic drugs (e.g., diphenhydramine): may counteract memantine’s action.